Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants

T P Do, A Al-Saoudi, M Ashina

13 Citationer (Scopus)

Abstract

Migraine is ranked as a leading cause of years lived with disability among all neurological disorders. Therapies targeting the calcitonin gene-related peptide (CGRP) signaling pathway, including monoclonal antibodies against the receptor or ligand and small molecule CGRP receptor antagonists (gepants), are today approved for migraine prophylaxis with additional compounds expected to be introduced to the market soon. In this review, we consider other putative prophylactic migraine drugs in development, including compounds targeting G-protein coupled receptors, glutamate, ion channels, and neuromodulatory devices. Emergence of these new interventions could complement our current treatment armamentarium for migraine management.

OriginalsprogEngelsk
TidsskriftRevue Neurologique
Vol/bind177
Udgave nummer7
Sider (fra-til)827-833
Antal sider7
ISSN0035-3787
DOI
StatusUdgivet - sep. 2021

Fingeraftryk

Dyk ned i forskningsemnerne om 'Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants'. Sammen danner de et unikt fingeraftryk.

Citationsformater